Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Iradimed (IRMD) Net Margin (2016 - 2026)

Iradimed has reported Net Margin over the past 14 years, most recently at 26.47% for Q1 2026.

  • Quarterly Net Margin rose 245.0% to 26.47% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 27.36% through Mar 2026, up 104.0% year-over-year, with the annual reading at 26.82% for FY2025, 56.0% up from the prior year.
  • Net Margin was 26.47% for Q1 2026 at Iradimed, down from 28.39% in the prior quarter.
  • Over five years, Net Margin peaked at 30.7% in Q3 2023 and troughed at 17.86% in Q4 2023.
  • The 5-year median for Net Margin is 25.91% (2023), against an average of 25.34%.
  • The largest YoY upside for Net Margin was 1050bps in 2022 against a maximum downside of -807bps in 2022.
  • A 5-year view of Net Margin shows it stood at 24.72% in 2022, then dropped by -28bps to 17.86% in 2023, then surged by 49bps to 26.54% in 2024, then increased by 7bps to 28.39% in 2025, then decreased by -7bps to 26.47% in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Net Margin are 26.47% (Q1 2026), 28.39% (Q4 2025), and 26.3% (Q3 2025).